Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDT with BF-200 ALA for Lentigo Maligna
NCT02685592Phase 4Completed
- Sponsor
- Päijät-Häme Wellbeing Services County
- Start
- Feb 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aminolevulinic acid 10% gel in lentigo maligna (LM), sponsored by Päijät-Häme Wellbeing Services County. Primary endpoint: The histopathological and immunohistochemical curing of lentigo maligna at 2 months. Started Feb 2016; status: completed.
02
Drugs
aminolevulinic acid 10% gel
03
Conditions
lentigo maligna (LM)
Beyond the preview
Go deeper on NCT02685592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685592.